Cytek Biosciences, Inc. — Director's Dealing 2021

Jul 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-27

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director)
Reporting Person: RA Capital Healthcare Fund LP (Director)
Reporting Person: RA Capital Nexus Fund II, L.P. (Director)
Reporting Person: Kolchinsky Peter (Director)
Reporting Person: Shah Rajeev M. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-27	Common Stock	C	5150751	—	Acquired	5150751	Indirect
2021-07-27	Common Stock	P	2762786	$17.00	Acquired	7913537	Indirect
2021-07-27	Common Stock	C	998553	—	Acquired	998553	Indirect
2021-07-27	Common Stock	P	187214	$17.00	Acquired	1185767	Indirect
2021-07-27	Common Stock	C	507724	—	Acquired	507724	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-27	Series D Preferred Stock	$	C	5150751	Disposed		Common Stock (5150751)	Indirect
2021-07-27	Series D Preferred Stock	$	C	998553	Disposed		Common Stock (998553)	Indirect
2021-07-27	Series D Preferred Stock	$	C	507724	Disposed		Common Stock (507724)	Indirect

Footnotes

F1: On July 27, 2021, each share of Series D Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").

F4: These securities are held directly by a separately managed account (the "Account").

F5: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.